BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34057733)

  • 1. Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility.
    Corsini EM; Mitchell KG; Zhou N; Bernatchez C; Forget MA; Haymaker CL; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Amaria RN; Jazaeri AA; Antonoff MB
    J Surg Oncol; 2021 Sep; 124(4):699-703. PubMed ID: 34057733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
    Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
    World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.
    Ben-Avi R; Itzhaki O; Simansky D; Zippel D; Markel G; Ben Nun A; Schachter J; Besser MJ
    J Immunother; 2016 Jun; 39(5):218-22. PubMed ID: 27163742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.
    Joseph RW; Peddareddigari VR; Liu P; Miller PW; Overwijk WW; Bekele NB; Ross MI; Lee JE; Gershenwald JE; Lucci A; Prieto VG; McMannis JD; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Hwu P; Radvanyi LG
    Clin Cancer Res; 2011 Jul; 17(14):4882-91. PubMed ID: 21632855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.
    Ben-Avi R; Farhi R; Ben-Nun A; Gorodner M; Greenberg E; Markel G; Schachter J; Itzhaki O; Besser MJ
    Cancer Immunol Immunother; 2018 Aug; 67(8):1221-1230. PubMed ID: 29845338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.
    Considine B; Hurwitz ME
    Methods Mol Biol; 2020; 2097():309-327. PubMed ID: 31776935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
    Svane IM; Verdegaal EM
    Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial.
    Khammari A; Nguyen JM; Leccia MT; Guillot B; Saiagh S; Pandolfino MC; Knol AC; Quéreux G; Chiffolettau A; Labarrière N; Dréno B
    Cancer Immunol Immunother; 2020 Aug; 69(8):1663-1672. PubMed ID: 32306076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.
    Ripley RT; Davis JL; Klapper JA; Mathur A; Kammula U; Royal RE; Yang JC; Sherry RM; Hughes MS; Libutti SK; White DE; Steinberg SM; Dudley ME; Rosenberg SA; Avital I
    Ann Surg Oncol; 2010 Jan; 17(1):163-70. PubMed ID: 19777192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
    Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
    J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases.
    Shrot S; Schachter J; Shapira-Frommer R; Besser MJ; Apter S
    Eur Radiol; 2014 Jun; 24(6):1251-6. PubMed ID: 24663820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience.
    Klapper JA; Davis JL; Ripley RT; Smith FO; Nguyen DM; Kwong KF; Mercedes L; Kemp CD; Mathur A; White DE; Dudley ME; Wunderlich JR; Rosenberg SA; Schrump DS
    J Thorac Cardiovasc Surg; 2010 Dec; 140(6):1276-82. PubMed ID: 20584535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
    Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
    Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
    J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.
    Goff SL; Smith FO; Klapper JA; Sherry R; Wunderlich JR; Steinberg SM; White D; Rosenberg SA; Dudley ME; Yang JC
    J Immunother; 2010 Oct; 33(8):840-7. PubMed ID: 20842052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
    Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
    Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
    [No Abstract]   [Full Text] [Related]  

  • 20. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
    Zippel D; Friedman-Eldar O; Rayman S; Hazzan D; Nissan A; Schtrechman G; Markel G; Schachter J; Itzhaki O; Besser MJ
    Anticancer Res; 2019 Sep; 39(9):4995-5001. PubMed ID: 31519606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.